Loading clinical trials...
Loading clinical trials...
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bayer
NCT05746039 · Obesity, Interstitial Lung Disease, and more
NCT03854071 · Heart Failure, Pulmonary Hypertension, and more
NCT07073820 · Pulmonary Hypertension
NCT07477197 · Adult Congenital Heart Disease, Pulmonary Hypertension, and more
NCT06899815 · Pulmonary Hypertension
La Jolla, California
Sacramento, California
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions